GLIOMATCH has successfully completed its first reporting period (RP1), covering activities from January 2024 to June 2025. This milestone was formally reviewed during the RP1 Review Meeting held on 26 September 2025, bringing together the consortium, external reviewers, and the European Health and Digital Executive Agency (HaDEA).
During the meeting, partners presented progress across all work packages, highlighting achievements in data management and governance, multi-omics integration, clinical data collection, and the development of advanced tools for patient stratification. The review also provided valuable feedback to guide the next phase of the project.
A new Results page is now available, providing access to public deliverables and scientific publications.
RP1 has established strong foundations for the project’s ambition to improve outcomes for glioblastoma and paediatric high-grade glioma patients through personalised, data-driven approaches. This includes the deployment of a robust data infrastructure and progress towards integrating spatial multi-omics and imaging data into clinical decision support tools.
As GLIOMATCH enters its next phase, the consortium will build on these achievements to further advance its immuno-oncology matchmaker platform and contribute to precision medicine in brain tumours.
